During the week of June 15, 2026, FDA issued 25 warning letters to telehealth companies over alleged false or misleading promotional claims about compounded GLP-1 productsclaims the agency views as violating the Federal Food, Drug, and Cosmetic Acts (FDCA) misbranding provisions, including Sections 502(a) and 502(n)
Consequently, 39 articles were included in the systematic review and dose-response network meta-analysis [11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49]
Passos, P
Pre-injection preparation Remove the prefilled syringe from the refrigerator 10-15 minutes before injection
Therapeutic use of GLP-1 tends to normalize alpha and beta cell sensitivity to glucose leading to improved glycemic control and reduced diabetic toxicity 7
Patient Advocacy: Support patient engagement in healthcare decisions